Skip to main content
Livermore
Livermore
ZHEN

SAB Biotherapeutics, Inc.

SABS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001833214

No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.

Other share classesSABSW

Q3 2024 vs. Q2 2024

How the institutions holding SAB Biotherapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of SABS: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders22225+5
Shares3.13M33.0K3.14M+47.5K (+1.5%)
Value$9.69M$102.2K$8.48M−$1.11M (−11.6%)

2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (7)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to SABS in Q3 2024
InstitutionSharesValue% of portfolio
HB Wealth Management, LLC108,600$293.2K0.00%
BlackRock, Inc.22,165$59.8K0.00%
Kovitz Investment Group Partners, LLC19,201$51.8K0.00%
Kestra Advisory Services, LLC11,930$32.2K0.00%
Citadel Advisors LLC10,305$27.8K0.00%
Sachetta, LLC100$2700.00%
Barclays PLC10$270.00%

Sold out (2)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of SABS in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Qube Research & Technologies Ltd6$19
Royal Bank of Canada6$0

Not filed for Q3 2024 yet (2)

Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SABS in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Institutional & Family Asset Management, LLC19,201$59.5K
BlackRock Inc.13,752$42.6K